97 related articles for article (PubMed ID: 17575547)
1. Induction of an antitumoral immune response by wild-type adeno-associated virus type 2 in an in vivo model of pancreatic carcinoma.
Eisold S; Schmidt J; Ryschich E; Gock M; Klar E; von Knebel Doeberitz M; Linnebacher M
Pancreas; 2007 Jul; 35(1):63-72. PubMed ID: 17575547
[TBL] [Abstract][Full Text] [Related]
2. Prevention of chemotherapy-related toxic side effects by infection with adeno-associated virus type 2.
Eisold S; Dihlmann S; Linnebacher M; Ryschich E; Aulmann M; Schmidt J; Schlehofer JR; Ridder R; von Knebel Doeberitz M
Int J Cancer; 2002 Aug; 100(5):606-14. PubMed ID: 12124812
[TBL] [Abstract][Full Text] [Related]
3. Effective antitumoral immune responses are not induced by cytosine deaminase suicide gene transfer in a syngeneic rat pancreatic carcinoma model.
Eisold S; Antolovic D; Schmidt J; Wiessner R; Klar E; von Knebel-Doeberitz M; Linnebacher M
Eur Surg Res; 2006; 38(6):513-21. PubMed ID: 17028434
[TBL] [Abstract][Full Text] [Related]
4. Lysates of S. pyogenes serotype M49 induce pancreatic tumor growth delay by specific and unspecific antitumor immune responses.
Linnebacher M; Maletzki C; Emmrich J; Kreikemeyer B
J Immunother; 2008 Oct; 31(8):704-13. PubMed ID: 18779749
[TBL] [Abstract][Full Text] [Related]
5. Pancreatic cancer regression by intratumoural injection of live Streptococcus pyogenes in a syngeneic mouse model.
Maletzki C; Linnebacher M; Kreikemeyer B; Emmrich J
Gut; 2008 Apr; 57(4):483-91. PubMed ID: 18025068
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-21 activates cytotoxic T lymphocytes and natural killer cells to generate antitumor response in mouse renal cell carcinoma.
Kumano M; Hara I; Furukawa J; Oniki S; Nagai H; Miyake H; Fujisawa M
J Urol; 2007 Oct; 178(4 Pt 1):1504-9. PubMed ID: 17707061
[TBL] [Abstract][Full Text] [Related]
7. Transient activation of tumor-associated T-effector/memory cells promotes tumor eradication via NK-cell recruitment: minimal role for long-term T-cell immunity in cure of metastatic disease.
Gu T; Kilinc MO; Egilmez NK
Cancer Immunol Immunother; 2008 Jul; 57(7):997-1005. PubMed ID: 18049819
[TBL] [Abstract][Full Text] [Related]
8. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH
Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269
[TBL] [Abstract][Full Text] [Related]
9. Interstitial quinacrine activates a distinctive immune response effective for tumor immunotherapy.
Sotelo J; Guevara P; Pineda B; Diaz C
Surgery; 2004 Sep; 136(3):700-7. PubMed ID: 15349121
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of anti-tumor immunity by high levels of Th1 and Th17 with a combination of dendritic cell fusion hybrids and regulatory T cell depletion in pancreatic cancer.
Yamamoto M; Kamigaki T; Yamashita K; Hori Y; Hasegawa H; Kuroda D; Moriyama H; Nagata M; Ku Y; Kuroda Y
Oncol Rep; 2009 Aug; 22(2):337-43. PubMed ID: 19578774
[TBL] [Abstract][Full Text] [Related]
11. CD8(+) T-cell responses to adeno-associated virus capsid in humans.
Mingozzi F; Maus MV; Hui DJ; Sabatino DE; Murphy SL; Rasko JE; Ragni MV; Manno CS; Sommer J; Jiang H; Pierce GF; Ertl HC; High KA
Nat Med; 2007 Apr; 13(4):419-22. PubMed ID: 17369837
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic efficacy of antitumor dendritic cell vaccinations correlates with persistent Th1 responses, high intratumor CD8+ T cell recruitment and low relative regulatory T cell infiltration.
Driessens G; Gordower L; Nuttin L; Stordeur P; Blocklet D; Egrise D; Velu T; Bruyns C
Cancer Immunol Immunother; 2008 Dec; 57(12):1745-56. PubMed ID: 18369621
[TBL] [Abstract][Full Text] [Related]
13. Sensitization of sarcoma cells to doxorubicin treatment by concomitant wild-type adeno-associated virus type 2 (AAV-2) infection.
Schwarzbach MH; Eisold S; Burguete T; Willeke F; Klein-Bauernschmitt P; Schlehofer JR; Herfarth C; Ridder R; von Knebel Doeberitz M
Int J Oncol; 2002 Jun; 20(6):1211-8. PubMed ID: 12012001
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy with dendritic cells pulsed with tumor-derived gp96 against murine lung cancer is effective through immune response of CD8+ cytotoxic T lymphocytes and natural killer cells.
Shinagawa N; Yamazaki K; Tamura Y; Imai A; Kikuchi E; Yokouchi H; Hommura F; Oizumi S; Nishimura M
Cancer Immunol Immunother; 2008 Feb; 57(2):165-74. PubMed ID: 17628800
[TBL] [Abstract][Full Text] [Related]
15. Intracerebral interleukin 12 induces glioma rejection in the brain predominantly by CD8+ T cells and independently of interferon-gamma.
Vetter M; Hofer MJ; Roth E; Pircher HP; Pagenstecher A
J Neuropathol Exp Neurol; 2009 May; 68(5):525-34. PubMed ID: 19525900
[TBL] [Abstract][Full Text] [Related]
16. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
[TBL] [Abstract][Full Text] [Related]
17. Potent antitumor effect of TRAIL mediated by a novel adeno-associated viral vector targeting to telomerase activity for human hepatocellular carcinoma.
Wang Y; Huang F; Cai H; Zhong S; Liu X; Tan WS
J Gene Med; 2008 May; 10(5):518-26. PubMed ID: 18338833
[TBL] [Abstract][Full Text] [Related]
18. Synergistic effect of intratumoral IL-12 and TNF-alpha microspheres: systemic anti-tumor immunity is mediated by both CD8+ CTL and NK cells.
Sabel MS; Arora A; Su G; Mathiowitz E; Reineke JJ; Chang AE
Surgery; 2007 Nov; 142(5):749-60. PubMed ID: 17981196
[TBL] [Abstract][Full Text] [Related]
19. Cross-talk between toll-like receptors 5 and 9 on activation of human immune responses.
Merlo A; Calcaterra C; Mènard S; Balsari A
J Leukoc Biol; 2007 Sep; 82(3):509-18. PubMed ID: 17586660
[TBL] [Abstract][Full Text] [Related]
20. Type 1 CD8+ T cells are superior to type 2 CD8+ T cells in tumor immunotherapy due to their efficient cytotoxicity, prolonged survival and type 1 immune modulation.
Ye Z; Tang C; Xu S; Zhang B; Zhang X; Moyana T; Yang J; Xiang J
Cell Mol Immunol; 2007 Aug; 4(4):277-85. PubMed ID: 17764618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
